Cargando…
Therapeutic Anti-KIR Antibody of 1–7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom
Glioblastoma (GBM) is the leading malignant intracranial tumor, where prognosis for which has remained extremely poor for two decades. Immunotherapy has recently drawn attention as a cancer treatment, including for GBM. Natural killer (NK) cells are immune cells that attack cancer cells directly and...
Autores principales: | Maeoka, Ryosuke, Nakazawa, Tsutomu, Matsuda, Ryosuke, Morimoto, Takayuki, Shida, Yoichi, Yamada, Shuichi, Nishimura, Fumihiko, Nakamura, Mitsutoshi, Nakagawa, Ichiro, Park, Young-Soo, Tsujimura, Takahiro, Nakase, Hiroyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531877/ https://www.ncbi.nlm.nih.gov/pubmed/37762486 http://dx.doi.org/10.3390/ijms241814183 |
Ejemplares similares
-
Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors
por: Nakazawa, Tsutomu, et al.
Publicado: (2022) -
Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors
por: Shida, Yoichi, et al.
Publicado: (2021) -
An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood
por: Nakazawa, Tsutomu, et al.
Publicado: (2023) -
CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma
por: Nakazawa, Tsutomu, et al.
Publicado: (2023) -
Natural Killer Cell-Based Immunotherapy against Glioblastoma
por: Morimoto, Takayuki, et al.
Publicado: (2023)